摘要
目的观察晚期胃癌化疗前后血清可溶性E2钙粘连蛋白(sEC)的浓度变化并探讨其临床意义。方法用酶联免疫吸附方法检测40例晚期胃癌初治患者接受FOLFOX4方案化疗前和化疗后第8周的血清sEC浓度,分析化疗前后血清sEC浓度及其变化与疗效的关系。结果 40例患者获CR2例,PR 12例,SD 13例,PD 13例。获有效组(CR+PR)患者化疗后的血清sEC浓度为(2082.36±590.32)ng/ml,显著低于化疗前的(2674.50±687.89)ng/ml(P<0.05);获SD和PD组患者化疗后血清sEC浓度较化疗前均显著升高(P<0.05);获SD和PD组患者化疗前基线sEC水平显著低于有效组(P<0.05)。结论化疗后血清sEC浓度下降可能与晚期胃癌FOLFOX4方案化疗疗效呈正相关,化疗前sEC浓度高的疗效好。
Objective To detect the expression of serum soluble E-cadherin（sEC） before and after chemotherapy in advanced gastric cancer patients,and discuss its clinical significance.Methods The levels of sEC in 40 gastric cancer patients were detected by enzyme linked immunosorbent assay（ELISA） before and 8 weeks after chemotherapy with FOLFOX 4 regimen.The correlation of levels of sEC and efficacy was analyzed.Results There were 2 cases of CR,12 cases of PR,13 cases of SD and 13 cases of PD.The levels of sEC after chemotherapy in objective response group was（2082.36±590.32）ng/ml,which was lower than that before chemotherapy（2674.50±687.89ng/ml）,showing significant differences（P0.05）.The changes of the levels of sEC in SD group and PD group were same as objective response group.The levels of sEC before chemotherapy in SD group and PD group were lower than that in objective response group.Conclusion The lower post-chemotherapy levels of sEC in gastric cancer patients has a positive correlation with objective response of FOLFOX 4 regimen.The patients with higher pre-chemotherapy levels of sEC may get better efficacy.
出处
《临床肿瘤学杂志》
CAS
2011年第9期820-822,共3页
Chinese Clinical Oncology
基金
河南省医学科技攻关基金资助项目(200804044)
